First-in-human trial of blood-brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound.

Abrahao A, Meng Y, Llinas M, Huang Y, Hamani C, Mainprize T, Aubert I, Heyn C, Black SE, Hynynen K, Lipsman N, Zinman L. · 2019

Read First-in-human trial of blood-brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound. by Abrahao A, Meng Y, Llinas M, Huang Y, Hamani C, Mainprize T, Aubert I, Heyn C, Black SE, Hynynen K, Lipsman N, Zinman L. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6763482.txt.

Introduction

Abrahao and co-authors report the first human trial of opening the blood-brain barrier in ALS using focused ultrasound. The barrier blocks most drugs from the brain. Guided by MRI, focused ultrasound can open it briefly and precisely. Four volunteers with amyotrophic lateral sclerosis took part. The target was the motor cortex, a movement area hit by the disease.

Imaging dye leaked at the target site in all four subjects right after treatment. The opening had closed again within 24 hours. No serious side effects appeared in clinical, scan, or electrical tests. Headache and frame discomfort were the main complaints. The result opens a path to delivering real ALS drugs to the brain.

Catalog record

CREATORAbrahao A, Meng Y, Llinas M, Huang Y, Hamani C, Mainprize T, Aubert I, Heyn C, Black SE, Hynynen K, Lipsman N, Zinman L.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE46 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6763482

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

First-in-human trial of blood–brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound By Agessandro Abrahao, Ying Meng, Maheleth Llinas, Yuexi Huang, Clement Hamani, Todd Mainprize, Isabelle Aubert, Chinthaka Heyn, Sandra E. Black, Kullervo Hynynen, Nir Lipsman, Lorne Zinman Published in: Nature Communications DOI: 10.1038/s41467-019-12426-9 ABSTRACT MR-guided focused ultrasound (MRgFUS) is an emerging technology that can accurately and transiently permeabilize the blood-brain barrier (BBB) for targeted drug delivery to the central nervous system. We conducted a single-arm, first-in-human trial to investigate the safety and feasibility of MRgFUS-induced BBB opening in eloquent primary motor cortex in four volunteers with amyotrophic lateral sclerosis (ALS). Here, we show successful BBB opening using MRgFUS as demonstrated by gadolinium leakage at the target site immediately after sonication in all subjects, which normalized 24 hours later. The procedure was well-tolerated with no serious clinical, radiologic or electroencephalographic adverse events. This study demonstrates that non-invasive BBB permeabilization over the motor cortex using MRgFUS is safe, feasible, and reversible in ALS subjects. In future, MRgFUS can be coupled with promising therapeutics providing a targeted delivery platform in ALS. INTRODUCTION Amyotrophic lateral sclerosis (ALS) remains a fatal neurodegenerative disease characterized by the progressive degeneration of both the upper and lower motor neurons (UMNs and LMNs). There is an incomplete understanding of the disease pathophysiology and current interventions only mildly slow disease progression. While preclinical studies in ALS rodent models have primarily focused on the distal-to-proximal motor neuron dying-back hypothesis1, recent data support a key pathological role of UMN in the motor cortex2. Signs of cortical neuronal and glial dysfunction have been observed early in the disease course and preceded spinal cord neuronal degeneration in ALS rodent models3,4, supporting a motor cortex driven dying-forward hypothesis2. Early cortical motor neuron dysfunction in ALS has also been demonstrated in human studies using transcranial magnetic stimulation, neuroimaging and electrophysiological measures2,5,6. Therefore, interventions that target cortical motor neurons alone or in combination with LMN-directed therapies may be essential in slowing or halting disease progression. Access to the neurons and glia of the primary motor cortex remains challenging as the blood–brain barrier (BBB) limits the transfer of therapeutics from the intravascular compartment. While there is preclinical and post-mortem evidence of abnormal BBB ultrastructure in ALS7,8, the BBB still restricts the passage of drugs, antibodies, gene carriers and stem cells from the capillaries to the central nervous system (CNS)9. Even riluzole, an approved drug for ALS, has limited availability in the brain tissue given BBB-related drug efflux mechanisms10. Presently, the targeted delivery of biotherapeutics to the brain requires an invasive neurosurgical procedure, which can have serious complications. Promising biotherapeutic approaches to UMN pathology in ALS, including neural progenitor cells11 and adeno-associated virus (AAV) expressing small-hairpin RNA to suppress mutant superoxide dismutase-1 (SOD1)3, have been surgically injected into the motor cortex of ALS rodents, resulting in significantly increased lifespan. Stereotactic implantation of autologous CD133+ stem cells into the primary motor cortex has also been investigated in a small cohort of ALS subjects with limited success12. Alternatively, non-invasive delivery methods across the BBB via facilitated transcellular transport (e.g., drug modifications with transferrin or insulin receptors13), drug efflux inhibition (e.g., elacridar10), or diffuse BBB breakdown (e.g., mannitol) lead to widespread CNS uptake and potential off-target effects. Given the limitations of open surgery and non-targeted pharmacological delivery approaches, the development of a non-invasive, image-guided method to safely and temporarily open the BBB for targeted delivery would represent a paradigm shift in the treatment of ALS. Transcranial magnetic resonance-guided focused ultrasound (MRgFUS) combined with intravenous ultrasound contrast (perflutren lipid microbubbles) has emerged as an incision-less technique to transiently open the BBB in targeted CNS regions14. The MRgFUS device is comprised of a multi-element phased array transducer system that can target virtually any brain region with millimetric accuracy, using real-time MRI feedback for tissue monitoring and intraoperative target guidance15. At higher frequencies, MRgFUS thalamotomy was found to be effective in treating medically refractory essential tremor in a randomized controlled trial16. At lower powers, ultrasound interacts with injected microbubbles resulting in transient mechanical disruption of the BBB without thermal injury17–19. This has been shown to enhance drug delivery to multiple brain regions in small-to-large animals, including cortical targets20, the hippocampus21, striatum21,22, and brainstem23. Although safe BBB opening in eloquent and non-eloquent brain regions has been demonstrated in subjects with high-grade gliomas using surgically implanted intracranial pulsed ultrasound device24,25, transcranial MRgFUS BBB opening is a non-invasive approach and has optimal spatial resolution for discrete and precise BBB targeting in eloquent regions, such as the primary motor cortex. In recent pilot clinical trials, non-invasive MRgFUS BBB opening in small and non-eloquent regions in and around gliomas26 and in the frontal lobe of patients with Alzheimer’s disease (AD)14 was safe and transient. This study represents the first-in-human trial testing the feasibility and safety of transient permeabilization of the BBB using MRgFUS in subjects with ALS. It is also the first attempt to apply this technology to eloquent cortical and subcortical tissue in human subjects as primary motor cortex was targeted using functional MRI (fMRI). Here, we show safe and reversible motor cortex BBB opening using MRgFUS at the target site immediately after sonication in all subjects without serious adverse events. RESULTS Participants and target ascertainment Four eligible subjects, two women and two men with median age 61 years (range: 56–70), diagnosed with ALS (probable El Escorial criteria) and clinical evidence of upper motor neuron dysfunction were enrolled in the study (Fig. 1). Table 1 lists their baseline demographics. Each subject’s sonication targets (Supplementary Fig. 1) were individualized according to arm (Fig. 2a) or leg (Fig. 3a) fMRI activation in the primary motor cortex to ascertain the homunculus topography. Hand activation by subject two and three was spatially shifted laterally from what is typically described as the hand knob area of the precentral gyrus. Cortical atrophy of the hand functional region was also noted on visual inspection at baseline in subject three, who presented with arm-onset phenotype. Subject four, who had leg-onset ALS, revealed bilateral motor cortex activation on fMRI.Fig. 1Trial profileTable 1Baseline patient characteristicsDisease duration (years)Site of ALS onsetaMRC sum score: ArmsbMRC sum score: LegsbSVCcALSFRS-R score (total 48)Modified Ashworth scoredMoCA score (total 30)Pre-existing conditionsALS specific treatmentSubject 14.2Lower extremity521983%32026HTN, IBS, GERD, chronic pain, osteoporosis, anxiety–Subject 24.3Upper extremity224757%30030HTN, migraine, childhood asthmaRiluzoleSubject 34.5Upper extremity276080%35027HTN, psoriasisRiluzole and EdaravoneSubject 44.1Lower extremity561669%33025Chronic pain-adefined as first reported weaknessbMedical Research Council (MRC) manual muscle strength rating for bilateral shoulder extensors, elbow flexors, elbow extensors, finger extensors, thumb flexor at the interphalangeal joint, abductor of the index finger and thumb abductors, hip flexors, hip abductors, knee extensors, knee flexors, ankle dorsiflexors and plantar flexors. Normal MRC sum score is 70 for both arms and 60 for both legscSlow vital capacity (SVC) was reported as percentage of the predicted for age, sex and body mass indexdZero indicates no spasticityALSFRS-R revised ALS Functional Rating Scale; Normal score equals 48, MoCA Montreal Cognitive Assessment; Normal score equals 30, HTN hypertension, IBS irritable bowel syndrome, GERD gastroesophageal reflux diseaseFig. 2Feasibility of blood–brain barrier opening using MRgFUS in the hand control region of the right primary motor cortex. a Hand control region mapping using motor-task functional MRI (fMRI). b, c show confirmation of successful blood–brain barrier permeabilization in the

Read the complete text